PranaX Corporation Closes $17 million Oversubscribed Series A Round

普拉纳X公司完成1700万美元超额认购的A轮融资

HOUSTON, January 29, 2026-- PranaX Corporation, a leading biotechnology company focused on regenerative biologics, today announced the closing of its oversubscribed $17 million Series A financing. The Series A round was led by family offices, trusts, and individual investors, a group with deep expertise across biotechnology, regenerative medicine, and healthcare innovation..

休斯顿，2026年1月29日——PranaX公司，一家专注于再生生物制品的领先生物技术公司，今天宣布其超额认购的1700万美元A轮融资完成。本轮融资由家族办公室、信托基金和个体投资者领投，这些投资者在生物技术、再生医学和医疗创新领域拥有深厚的专业知识。

The financing comes amid growing recognition of the exosome wellness sector as a promising frontier in regenerative medicine. As consumer and provider demand shifts toward science-backed, biologically informed solutions that support healthy aging and overall quality of life, exosomes are increasingly viewed as a foundational component of next-generation regenerative strategies.

这笔融资正值外泌体健康领域作为再生医学的一个有前景的前沿领域受到越来越多认可之际。随着消费者和供应商的需求逐渐转向有科学依据、基于生物学的支持健康老龄化和整体生活质量的解决方案，外泌体正日益被视为下一代再生策略的基础组成部分。

PranaX continues to push the field forward by developing exosome-based technologies that may deliver transformative benefits to retain or restore quality of life. PranaX envisions a world where the limitations of aging and degeneration are no longer barriers to a long fulfilling life..

PranaX 通过开发基于外泌体的技术，不断推动该领域向前发展，这些技术可能会带来保持或恢复生活质量的变革性益处。PranaX 展望一个世界，在这个世界里，衰老和退化的限制不再成为过上长久而充实生活的障碍。

'PranaX was founded on the belief that exosomes can redefine how we approach aging and long-term wellness,' said Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX. 'We are building a science-driven platform that bridges rigorous biological understanding with real-world impact. This financing validates both our mission and our differentiated approach, and it positions us to scale thoughtfully while remaining grounded in scientific integrity.'.

“PranaX 的创立基于这样的信念：外泌体可以重新定义我们对待衰老和长期健康的方式，”PranaX 创始人兼首席运营官 Steven J. Greco 博士表示。“我们正在构建一个以科学为驱动的平台，将严谨的生物学理解与现实世界的影响相结合。这笔融资既验证了我们的使命，也验证了我们独特的方法，同时也使我们能够在保持科学诚信的同时进行深思熟虑的扩展。”

Proceeds from the Series A financing will be used to advance PranaX's research and development initiatives, expand scientific and operational infrastructure, support strategic partnerships, and accelerate product development and commercialization efforts. As PranaX enters its next phase of growth, the company remains committed to advancing the future of regenerative biologics through responsible innovation, scientific rigor, and a steadfast focus on improving quality of life..

A轮融资的收益将用于推进PranaX的研发计划，扩展科学和运营基础设施，支持战略合作伙伴关系，并加速产品开发和商业化进程。随着PranaX进入下一个增长阶段，公司将继续通过负责任的创新、科学严谨性以及始终专注于改善生活质量，推动再生生物制品的未来发展。

About PranaX

关于PranaX

PranaX is a regenerative biotechnology company dedicated to harnessing stem cell-derived exosomes through evidence-based science. The company's overarching mission is to unlock the properties of exosomes to promote wellness and lead individuals towards healthier, more fulfilling lives. The company's research, development, and manufacturing operations are headquartered within the Levit Green life science campus in Houston, Texas..

PranaX 是一家再生生物技术公司，致力于通过基于证据的科学利用干细胞衍生的外泌体。公司的总体使命是挖掘外泌体的特性以促进健康，并引导人们走向更健康、更有意义的生活。公司研发和制造业务总部位于德克萨斯州休斯顿的Levit Green生命科学园区。